• S-Biomedic announces topline results of a successful clinical study in acne

    Friday November 26th 2021

  • Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Tuesday November 23rd 2021

  • OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)

    Monday November 15th 2021

  • Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

    Wednesday October 13th 2021

  • Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer

    Wednesday October 6th 2021

  • Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

    Monday October 4th 2021

  • Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

    Monday October 4th 2021

  • OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Thursday September 30th 2021

  • Your news here?

  • Mithra announces topline results for COVID-19 Phase II Study

    Friday September 24th 2021

  • Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study

    Wednesday September 22nd 2021

  • Precirix and IFE sign clinical trial manufacturing agreement

    Monday September 13th 2021


Strategic Partners